This study reports the preparation and characterization of cysteine-terminated B-domain (Bd-cys) of Staphylococcus aureus protein A, in combination with immunoglobulin G (IgG) antibodies directed against the q1 and a1 subunits of GABA A receptors, for localizing reagents of interest to the target receptor. A cysteine residue was inserted at the C terminus of the cysteine-lacking B-domain (Bd) and used for conjugating maleimide-containing compounds. As determined by enzyme-linked immunosorbent assay (ELISA), binding of a Bd-cys-S-fluorescein conjugate to polyclonal guinea pig anti-GABA A -q1 and rabbit anti-GABA A -a1 IgG was similar to that exhibited by full-length protein A. Surface plasmon resonance analysis of the interaction of Bd-cys-S-PEG3400-biotin conjugate (where PEG is polyethylene glycol) with anti-GABA A -q1 and anti-GABA A -a1 yielded K D values of 6.4 ± 1.9 and 0.4 ± 0.1 nM, respectively. Fluorescence anisotropy analysis of the binding of Bd-cys-S-fluorescein to the two antibodies yielded EC 50 values of 65 and 18 nM, respectively. As determined with biotin-reactive fluorescent reagents, Bd-cys-S-PEG3400-biotin specifically bound to the plasma membrane of Xenopus laevis oocytes that expressed a1b2c2 or homomeric q1 GABA A receptors and were pretreated with the corresponding anti-GABA A IgG. The IgG-binding specificity and high affinity of Bd-cys conjugates illustrate the potential of these conjugates, in combination with a selected IgG, to localize compounds of interest at specific cell surface proteins.
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Staphylococcal protein A (SpA), 1 a cell wall-associated protein of Staphylococcus aureus bacteria [1] , protects S. aureus against the host's immune system by binding to host antibodies [2] [3] [4] [5] . SpA consists of a tandem sequence of five homologous repeats termed (sequentially from the N terminus) domains E, D, A, B, and C [6] [7] [8] .
Each of these domains is arranged as three helices [5, 9] and binds to the Fc fragment of immunoglobulin G (IgG) [5, 10, 11] . The Bdomain (Bd), a 58-amino acid segment ($7 kDa) that lacks cysteine residues, has been studied extensively as a representative domain of SpA. The similar IgG-binding affinity of Bd and parent SpA [5, [11] [12] [13] , together with Bd's ease of bacterial expression and high solubility, has motivated interest in designing affinity reagents based on the Bd structure [2, 12, [14] [15] [16] [17] .
The robust IgG-binding activity of Bd, along with its small size and defined structure, makes Bd, in combination with an IgG directed against the ectodomain of a cell surface protein, a potentially versatile scaffold for localizing reagents at the target protein. Our motivation for investigating such an approach comes, in particular, from recent studies demonstrating the light-controlled activation or blockage of ion channels by photosensitive analogs of channel ligands that are anchored to a mutant (cysteine-substituted) form of the channel [18] [19] [20] . That is, conjugating Bd with a physiologically active analog of the channel ligand, and interfacing the Bd/ ligand conjugate with an IgG that binds to the channel's ectodomain, might enable modulation of the activity of the native ion channel, avoiding the need to express a mutant (i.e., anchoring) form of the channel in the target cell. Mazzucchelli et al. [21] , in a recent study addressing the targeting of HER2 membrane receptors with magnetic beads, conjugated the beads with a form of Bd that had been modified to contain multiple cysteine residues (which served as the bead anchoring site), interfaced the Bd/bead conjugate with a monoclonal anti-HER2 antibody, and, with use of fluorescein isothiocyanate (FITC)-labeled secondary antibody directed against the monoclonal antibody, demonstrated HER2 receptor labeling. To our knowledge, however, no one has studied the workability of engineered Bd as an IgG-associated scaffold for targeting ion channel proteins.
GABA A receptors, an abundant and widely distributed class of heteropentameric ion channels that are gated by the neurotransmitter c-aminobutyric acid (GABA) and mediate neural signaling at numerous locations in the central nervous system (CNS), including the retina, are a logical target for physiological modulation by a ligand localized at the receptor's ectodomain (cf. Refs. [18] [19] [20] ).
Among the 19 known subunits of GABA A receptors are a1, a component of the a1b2c2 GABA A subtype found in many neural tissues [22, 23] , and q1, a component of GABA A -q receptors (also known as GABA C receptors) whose distribution includes multiple locations within the retina [23] [24] [25] [26] . As a step toward developing a ligandanchoring system for GABA receptors, we have prepared a cysteine-terminated form of Bd (here termed Bd-cys) and conjugated Bd-cys with maleimide-terminated test reagents. The experiments employed a single cysteine inserted at the end of Bd's third a-helix, a site distinct from the Fc-binding positions on the first and second a-helices [2, 27] . The absence of native cysteine residues in Bd [12] avoids the possibility of unwanted intramolecular disulfide linkage to the introduced cysteine [21] . The introduced cysteine is, however, capable of forming intermolecular disulfide linkages with another cysteine-terminated Bd, forming a Bd-cys dimer. With the use of appropriate IgG antibodies, we tested the ability of complexes consisting of IgG and Bd-cys-tethered reagents to interact with GABA A q1 and a1 subunits.
Materials and methods

Preparation of SpA, Bd, and Bd-cys
Plasmid DNA from Escherichia coli with the pGX2907 plasmid containing the S. aureus genome, including the full SpA sequence (American Type Culture Collection, ATCC 39344, Manassas, VA, USA; SpA gene NCBI accession number J01786), was used as a template for polymerase chain reaction (PCR) preparation of DNA fragments coding for wild-type SpA and wild-type Bd. PCR was performed using Pfu polymerase (Promega, Madison, WI, USA) and primers designed to allow cloning of the PCR products into the Champion pET-100 TOPO cloning and expression system (Invitrogen by Life Technologies, Carlsbad, CA, USA), which features the addition of a hexahistidine fusion tag at the N terminus followed by an enterokinase cleavage site to the protein of interest. Primers were as follows: SpA (forward: 5 0 -CAC CGC GCA ACA CGA TGA A-3 0 ; reverse: 5 0 -TTA TAG TTC GCG ACG ACG TCC A-3 0 ); Bd (forward: 5 0 -CAC CGC TGA TAA CAA ATT C-3 0 ; reverse: 5 0 -CTA TTT TGG TGC TTG TGC ATC-3 0 ). PCR products were ligated to a TOPO plasmid and transformed into XL-1 One Shot TOPO competent cells, sequenced, and subcloned. In addition, the TOPO plasmid containing the coding sequence for Bd was used as a template for preparation of Bd containing cysteine at the C terminus. The procedure for cysteine addition was similar to that described above, with the following primers (cys codon underlined): forward, 5 0 -GCA CAA GCA CCA AAA TGT TAG AAG GGC GAG CTC-3 0 ; reverse, 5 0 -GAG CTC GCC  CTT CTA ACA TTT TGG TGC TTG TGC-3 0 . Plasmid DNA of the SpA, Bd, and Bd-cys clones was transformed into BL-21 star E. coli for protein expression. Lysis of the cell pellets was performed using the BugBuster with Benzonase protein extraction kit (Novagen/EMD Biosciences, Madison, WI, USA) with lysozyme and protease inhibitor cocktail added. Proteins were purified from the supernatant by affinity chromatography using HiTrap affinity columns (GE Healthcare, Piscataway, NJ, USA). Prior to analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE, 4-20% acrylamide gradient, Bio-Rad, Hercules, CA, USA), sample aliquots were prepared in buffer that either contained 5% (v/v) b-mercaptoethanol (b-ME) (reducing buffer) or lacked b-ME (nonreducing buffer). Gels were then run and stained by Coomassie blue.
Preparation of Bd-cys conjugates
Because affinity-purified Bd-cys consisted largely of dimers linked by a disulfide bond (see Results), linkage of Bd-cys to the investigated ligands fluorescein (FL)-5-maleimide (Fisher Scientific, Pittsburgh, PA, USA) and maleimide-PEG3400-biotin (where PEG is polyethylene glycol) (Laysan Bio, Arab, AL, USA) was carried out under reducing conditions. The FL-5-maleimide and maleimide-PEG3400-biotin conjugates were prepared by adding 200 ll of 6 lM (largely dimerized) Bd-cys to each of several wells of a HIS-Select high-capacity nickel-coated plate (Sigma-Aldrich, St. Louis, MO, USA) and incubation overnight at 4°C. Following three washes with TBST buffer (Tris-buffered saline with Tween 20:
10 mM Tris, 150 mM NaCl, and 0.1% Tween 20), 200 ll of freshly prepared 100 mM dithiothreitol (DTT) reducing agent in water was added to the empty wells, and the plate was incubated for 40 min at 37°C. Immediately following five washes with TBST ($5 min total), 120 lM of thiol-reactive FL-5-maleimide or maleimide-PEG3400-biotin was added, forming the thioether product Bd-cys-S-FL or Bd-cys-S-PEG3400-biotin, respectively. The plate was incubated for 2 h at room temperature and then washed three times with TBST. The conjugate was removed from the plate by incubation with 500 mM imidazole buffer for 20 min at room temperature. Bd-cys conjugate solutions were then pooled, concentrated to 1 to 2 mg/ml, and dialyzed against phosphate-buffered saline (PBS); aliquots were then prepared in reducing buffer (5% b-ME) or nonreducing buffer and analyzed by SDS-PAGE. Experiments were also conducted on preparations that, by design, were dominated by Bd-cys dimer. FL-labeled Bd-cys dimer conjugate was prepared by FL labeling of HiTrap Ni-column purified Bd-cys dimer (4-6 FLs/protein) and purification according to the manufacturer's instructions, using the FluoroTag FL conjugation kit (FITC1-1KT, Sigma-Aldrich). The FL-labeled product was concentrated to 1 to 2 mg/ml and dialyzed against PBS. This FL-labeled Bd-cys dimer was then analyzed by SDS-PAGE under reducing or nonreducing conditions.
Enzyme-linked immunosorbent assay
The interaction of Bd-cys-S-FL monomer and of FL-labeled Bdcys dimer with IgG was tested using an enzyme-linked immunosorbent assay (ELISA) similar to that described previously [12] . 0 -azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) liquid substrate (Sigma-Aldrich) was added, and the plate was incubated at room temperature for 30 to 40 min. Three separate wells received the ABTS substrate only (i.e., no protein preparation and no antibody) and were termed blank wells. Raw absorbance values at k = 405 nm (A 405 ) were determined (GENios Pro plate reader, Tecan Group, Männedorf, Switzerland). For each well, net absorbance was defined as A 405 (sample well) -A 405 (blank well).
Surface plasmon resonance
The binding of Bd-cys-S-PEG3400-biotin to anti-GABA A -q1 and anti-GABA A -a1 antibodies was analyzed by surface plasmon resonance (SPR, Biacore T100, GE Healthcare). All SPR experiments were performed at room temperature. In the first type of experiment, which was designed to establish an antibody-binding profile, Bd-cys-S-PEG3400-biotin was immobilized on a flow cell of a pre- 
Fluorescence anisotropy
The binding of Bd-cys-S-FL and FL-labeled Bd-cys dimer to anti-GABA A -q1 and anti-GABA A -a1 antibodies was also analyzed by fluorescence anisotropy (FA, POLARstar OPTIMA Microplate Reader, BMG Labtech, Cary, NC, USA). Each experiment testing guinea pig anti-GABA A -q1 IgG and rabbit GABA A -a1 IgG, as well as rat IgG2a and chicken IgY controls, involved study of a group of 42 mixtures. Each mixture, 50 ll in volume, contained 15 nM FLlabeled Bd-cys conjugate (Bd-cys-S-FL or FL-labeled Bd-cys dimer) and antibody at a concentration ranging from 0.078 to 200 nM (14 different concentrations, triplicate samples for each concentration). In addition, as control experiments, groups of samples (30 mixtures, each 50 ll in volume, per group) containing 15 nM ubiquitin-FL and anti-GABA A -a1, rat IgG2a, or chicken IgY at concentrations ranging from 1.25 to 200 nM (triplicates at each concentration) were prepared. The mixtures were incubated overnight at 4°C, added to a 96-well microplate, and analyzed by FA. Using MARS data analysis software (BMG Labtech), a fourparameter curve was fitted to the data set. For both Bd-cys-S-FL and FL-labeled Bd-cys dimer, binding to the anti-GABA A -q1 and anti-GABA A -a1 antibodies was analyzed in two FA experiments, each of the type just described. The excursions of the fitted four-parameter curves in these experiments (i.e., the vertical [ordinate] distances between the lower and upper asymptotes of the fitted curves) were as follows (in units of milli-anisotropy [mA]): 43 and 49 for (Bd-cys-S-FL, anti-GABA A -q1), 40 and 42 for (Bd-cys-S-FL, anti-GABA A -a1), 78 and 83 for (FL-labeled Bd-cys dimer, anti-GABA A -q1), and 12 and 11 for (FL-labeled Bd-cys dimer, anti-GABA A -a1). For both Bd-cys-S-FL monomer and FL-labeled Bd-cys dimer, there was no change in mA with varying antibody concentrations when the Bd-cys preparation was incubated with either rat IgG2a or chicken IgY. Similarly, there was no change in mA with antibody concentration for the preparations consisting of (ubiquitin-FL, anti-GABA A -a1), (ubiquitin-FL, rat IgG2a), or (ubiquitin-FL, chicken IgY). Each data point from the experiment was referenced to the minimum (i.e., low-concentration asymptotic) value of the fitted curve and normalized to the excursion of this curve. The referenced, normalized data obtained in each experiment were averaged. Using OriginPro software (OriginLab, Northampton, MA, USA), the averaged data were then analyzed through the equation
where y/y 0 is the normalized anisotropy value at a given concentration of antibody, x is the antibody concentration, and EC 50 is a fitted parameter.
Oocyte preparation and fluorescence imaging
All animal procedures conformed with institutional policies and with the Statement for the Use of Animals in Ophthalmic Research adopted by the Association for Research in Vision and Ophthalmology. Xenopus laevis oocytes expressing human q1 GABA A or a1b2c2 GABA A receptors (a1, b2, and c2 subunits of rat, rat, and human, respectively) were prepared as described previously [25, 29, 30] . Briefly, messenger RNA (mRNA), obtained for each selected sequence from in vitro transcription (mMessage mMachine, Ambion/Applied Biosystems by Life Technologies, Austin, TX, USA) from linearized complementary DNAs (cDNAs), was injected into the oocytes (Drummond Nanoject II, Drummond Scientific, Broomall, PA, USA). Oocytes were analyzed for GABA receptor expression after 24 to 72 h of incubation in physiological saline (100 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, and 10 mM glucose, pH 7.2-7.4) containing 0.1 mg/ml gentamicin at 16°C. Immunofluorescence labeling of oocytes expressing either GABA A q1 or GABA A a1b2c2 receptors and nonexpressing control oocytes involved, sequentially, a blocking step with 10% fetal bovine serum and 1% bovine serum albumin diluted in physiological saline (1 h, room temperature), three or four washes with physiological saline, and a 1-h incubation at room temperature with 20 lg/ml primary antibody (guinea pig anti-q1, rabbit anti-a1) or in the absence of antibody as a control. Following three or four washes with physiological saline, oocytes were incubated for 1 h at room temperature either with 100 nM Bd-cys-S-PEG3400-biotin with streptavidin-DyLight 488 (Fisher Scientific) or with 100 nM FL-conjugated Bd-cys dimer. Following six washes, oocytes were visualized and imaged using a Leica DM-IRE2 confocal microscope (Leica Microsystems, Buffalo Grove, IL, USA) at 20Â magnification [28, 29] .
Results
Preparation and cysteine reactivity of Bd-cys monomer
The Bd component of the desired conjugate consisted of monomeric Bd containing a terminating cysteine, to which the test ligand was attached. Although the absence of other cysteines in the Bd monomer precluded intramolecular disulfide bond formation, Bd-cys monomers were capable of intermolecular disulfide linkage (i.e., dimerization). Thus, the preparation of monomeric Bd-cys necessitated the reduction of dimerizing disulfide bonds that formed upon the expression and affinity purification of the protein. To determine the extent of contamination of conjugated Bd-cys preparations (Bd-cys-S-FL, FL-labeled Bd-cys dimer, and Bd-cys-S-PEG3400-biotin) by Bd-cys dimers, aliquots of these preparations were analyzed by SDS-PAGE in reducing conditions (i.e., dilution in buffer containing b-ME prior to loading onto the gel) or nonreducing conditions (i.e., buffer lacking b-ME). Fig. 1A illustrates data obtained in nonreducing conditions. Shown in lane 1 are results obtained for affinity-purified Bd-cys. Lanes 2 to 4 show samples resulting from conjugation of the affinity-purified Bd-cys with maleimide-FL (lane 2), with FITC (lane 3), and with maleimide-PEG3400-biotin (lane 4). These four samples contained varying contributions from the dimer form of Bd-cys. Specifically, as normalized to the combined density of the monomer and dimer bands in a given lane, the dimer contributions in lanes 1 to 4 were 0.63, 0.25, 0.65, and 0.51, respectively. When the samples were treated with b-ME prior to loading onto the gel (Fig. 1B) , Bd-cys was efficiently converted to monomer (normalized dimer contributions of 60.1 for all lanes), consistent with the reduction of disulfide bonds under the reducing conditions. Together, the results in Fig. 1A and B indicate that, following the standard treatment with DTT as part of the preparation of the conjugates, contaminating dimers remained in the final product. This contamination presumably reflected incomplete reduction by DTT and/or the re-formation of dimerizing disulfide linkages during subsequent washes (which removed DTT) or during the conjugation reaction (which was carried out in the absence of DTT). As a measure of the possible effects of dimer in the conjugate preparations, the examination of Bd-cys-binding kinetics and of oocyte surface interaction (see below) also included tests of preparations that, by design, were dominated by dimer (i.e., not subjected to the reducing preparative step).
To compare the IgG-binding affinity of the Bd-cys construct with that of SpA, and because guinea pig and rabbit IgGs were used as the two investigated anti-GABA A subunit antibodies, we employed ELISA to assess the binding of Bd-cys monomer and dimer to HRP-conjugated guinea pig IgG and rabbit IgG. Fig. 2A shows net absorbance data (sample minus blank; see Materials and Methods) obtained for the binding of Bd-cys-S-FL monomer and SpA to the HRP-conjugated IgG preparations. There were no significant differences in binding of Bd-cys-S-FL and SpA to HRP-guinea pig IgG (0.91 ± 0.14 and 0.84 ± 0.04, respectively, P = 0.43) or to HRPrabbit IgG (1.13 ± 0.11 and 1.25 ± 0.04, respectively, P = 0.16). Furthermore, net absorbance data obtained for the binding of both Bd-cys-S-FL and SpA to both IgG preparations significantly exceeded those obtained from TBST controls from which Bdcys-S-FL or SpA was omitted (P = 7.2 Â 10 À5 and 2.45 Â 10
À5
[HRP-guinea pig IgG] and 2.42 Â 10 À4 and 1.28 Â 10 À5 [HRPrabbit IgG], respectively). Fig. 2B shows that, as with monomer Bd-cys-S-FL in Fig. 2A , net absorbance for the binding of unlabeled Bd-cys dimer and FL-labeled Bd-cys dimer to the IgG preparations also significantly exceeded those of TBST controls (P = 2.0 Â 10 À6 and 2.9 Â 10 À4 [HRP-guinea pig IgG] and 1.8 Â 10 À7 and 1.8 Â 10
À5 [HRP-rabbit IgG], respectively). Although higher than the net absorbance for TBST controls, net absorbances for the binding of FL-labeled Bd-cys dimer (0.16 ± 0.02 for HRP-guinea pig IgG and 0.21 ± 0.01 for HRP-rabbit IgG) were significantly less than those for unlabeled Bd-cys dimer (0.85 ± 0.04 for HRP-guinea pig IgG and 0.98 ± 0.02 for HRP-rabbit IgG) and for SpA (0.84 ± 0.04 for HRP-guinea pig IgG and 1.25 ± 0.04 for HRP-rabbit IgG) (P < 0.001).
Affinity and kinetics of binding to anti-GABA A -q1 and anti-GABA A -a1 antibodies
Surface plasmon resonance Using a streptavidin-coated chip, we examined binding of the anti-GABA A -q1 and anti-GABA A -a1 antibodies to a surface immobilized with Bd-cys-S-PEG3400-biotin. The top panel of Fig. 3 shows results obtained when anti-GABA A -a1 (arrow 1) and anti-GABA A -q1 (arrow 3) were introduced to a flow cell containing immobilized Bd-cys-S-PEG3400-biotin. The response produced by antibody binding for anti-GABA A -a1 and anti-GABA A -q1 amounted to approximately 2000 and 800 RU, respectively. The larger size of the response to anti-GABA A -a1 is consistent with the somewhat stronger affinity of Bd-cys-S-PEG3400-biotin to the anti-GABA A -a1 described in Fig. 2A . Also shown in the top panel of Fig. 3 are responses to rat IgG2a (arrow 2) and chicken IgY (arrow 4), two types of immunoglobulin known not to be reactive with SpA [3, 31] ; no substantial signal was produced with either of these immunoglobulins or with chicken anti-insulin IgY (arrow 5; see below). The bottom panel of Fig. 3 shows results from an experiment in which insulin-biotin was used as a control capture agent. Here, chicken anti-insulin IgY (positive control) showed a substantial signal, but neither anti-GABA A -a1 (arrow 1), anti-GABA A -q1 (arrow 3), rat IgG2a (control; arrow 2), nor chicken IgY (control; arrow 4) produced a significant signal. Overall, the Fig. 3 data indicate a specificity of interaction of the Bd-cys monomer with the two investigated anti-GABA A subunit antibodies.
Binding affinities and kinetics of the interactions of anti-GABA A -q1 and anti-GABA A -a1 antibodies with Bd-cys-S-PEG3400-biotin were investigated over the concentration range of 0.625 to 20 nM (10-ll/min flow rate and 240-s incubation time). To test for the possible influence of a mass transfer effect (i.e., of antibody flow rate) [32] on the kinetics of interaction of Bd-cys-S-PEG3400-biotin with the anti-GABA A subunit antibodies, data were obtained with The results indicate a close fit of the binding curves to the sensograms obtained for anti-GABA A -q1 and anti-GABA A -a1 antibodies. Table 1 shows K D values of 6.4 ± 1.9 and 0.4 ± 0.1 nM determined for the interaction of Bd-cys-S-PEG3400-biotin with anti-GABA Aq1 and anti-GABA A -a1, respectively. These K D values, in addition to k a and k d data in Table 1 , indicate high affinity of this Bd-cys monomer conjugate for anti-GABA A -q1 guinea pig IgG and anti-GABA A -a1 rabbit IgG. The k a and K D values for the binding of Bdcys-S-PEG3400-biotin to anti-GABA A -a1 rabbit IgG indicate slightly higher affinity for this IgG than for the guinea pig IgG. Data obtained with the addition of rat IgG2a and chicken IgY negative controls to immobilized Bd-cys-S-PEG3400-biotin and insulin-biotin, as well as the addition of the rabbit anti-GABA A -a1 IgG and guinea pig anti-GABA A -q1 IgG to immobilized insulin-biotin, showed no change in the response and, thus, indicated the absence of binding.
Fluorescence anisotropy
In FA experiments, we investigated the binding of (monomeric) Bd-cys-S-FL, FL-labeled Bd-cys dimer, and (as a negative control) FL-labeled ubiquitin to anti-GABA A -q1 and anti-GABA A -a1 as well as to (negative controls) rat IgG2a and chicken IgY. Figs. 5A and B show data for referenced/normalized anisotropy as a function of antibody concentration (nM) for the binding of Bd-cys-S-FL to anti-GABA A -q1 and anti-GABA A -a1, respectively. Analysis of these data through Eq. (1) yielded EC 50 values of 65 and 18 nM, respectively (Table 1) . Similarly, Fig. 5C and D illustrate plots of referenced/normalized anisotropy versus antibody concentration for the binding of FL-labeled Bd-cys dimer to anti-GABA A -q1 and anti-GABA A -a1, respectively. Analysis of these plots yielded EC 50 values of 93 and 25 nM, respectively ( Table 1 ). The Fig. 5D and Table 1 results describing the interaction of FL-labeled Bd-cys dimer with anti-GABA A -a1 should be taken as only a relatively rough estimate because the absolute range of FA signal amplitudes obtained for this interaction was relatively small (see Materials and Methods text noting excursions of fitted curves in the FA analysis). We furthermore examined, by FA, the binding of Bd-cys-S-FL and FL-labeled Bd-cys dimer to control immunoglobulins that do not bind to SpA (rat IgG2a and chicken IgY) [3] . Shown in Fig. 5E are raw data for anisotropy (mA) versus antibody concentration (nM) obtained for the binding of Bd-cys-S-FL (closed symbols) and FLlabeled Bd-cys dimer (open symbols) to rat IgG2a (circles) and chicken IgY (triangles). By contrast with results obtained for binding to anti-GABA A -q1 and anti-GABA A -a1, none of the four conditions examined in Fig. 5E yielded a systematic increase in anisotropy with increasing antibody concentration. Analysis of the data failed to yield a smooth function of substantial ordinate excursion; thus, the data could not be normalized as in Fig. 5A-D. Control experiments (Fig. 5F ) testing the binding of FL-labeled ubiquitin (8.5 kDa) to anti-GABA A -a1, rat IgG2a, and chicken IgY also failed to yield a systematic increase in anisotropy with increasing antibody concentrations.
Binding of B-domain/IgG to oocytes expressing GABA A receptors
By fluorescence microscopy, we investigated the interaction of Bd-cys monomer conjugates with anti-GABA A subunit antibodies that were prebound to the surface membrane of Xenopus oocytes expressing homomeric GABA A -q1 and a1b2c2 GABA A receptors (Fig. 6 ). In the experiment described by column 1 of Fig. 6A , a GABA A -q1-expressing oocyte was treated, sequentially, with anti-GABA A -q1 guinea pig IgG, Bd-cys-S-PEG3400-biotin, and streptavidin-DyLight 488 (see Materials and Methods). This treatment led to the appearance of a fluorescence halo at the surface membrane of the (approximately spherical) oocyte. Columns 2 and 3 of Fig. 6A shows results obtained from two control oocytes: a GABA A -q1-expressing oocyte that was treated only with Bd-cys-S-PEG3400-biotin and streptavidin-DyLight 488 (i.e., primary antibody omitted) (column 2) and a nonexpressing oocyte that received the same treatment as the oocyte of column 1. As illustrated in the images in columns 2 and 3, both control preparations exhibited little, if any, fluorescence halo. In summary, the Fig. 6A data indicate the binding of anti-GABA A -q1 antibody to the GABA A -q1-expressing oocyte and the binding of Bd-cys-S-PEG3400-biotin to the receptor-bound primary antibody. As shown in Fig. 6B , treatment of a1b2c2 GABA A -expressing oocytes with Bd-cys-S-PEG3400-biotin similarly indicated specific binding of the Bd-cys-S-PEG3400-biotin to receptor-bound anti-GABA A -a1 antibody. In addition, FL-labeled Bd-cys dimer exhibited specific binding to receptorbound anti-GABA A -q1 and anti-GABA A -a1 IgG (Fig. 6C and D ).
Discussion
The current study has described the preparation of Bd-cys of SpA and, in combination with IgG antibodies, the investigation of Bd-cys as a scaffold for localizing compounds of interest to oocyte-expressed q1 and a1b2c2 GABA A receptors. The results show that when Bd-cys is conjugated with either maleimide-FL or maleimide-PEG3400-biotin, binding affinities of the conjugate for anti-GABA A -q1 and anti-GABA A -a1 IgG are similar to those exhibited by full-length SpA ( Fig. 2A and B) . This finding, along with the observed binding of Bd-cys-S-PEG3400-biotin/IgG complex to oocyte-expressed q1 and a1b2c2 GABA A receptors ( , respectively (Table 1) , consistent with previously reported values for SpA and its domains [5, 11, [33] [34] [35] . The FA experiments yielded EC 50 values of 65 and 18 nM for the binding of the Bd-cys-S-FL monomer to guinea pig anti-GABA A -q1 and rabbit anti-GABA A -a1 antibodies, respectively (Table 1) . These nM-range values of K D and EC 50 indicate strong affinity of the Bd-cys conjugate for the two antibodies and are in agreement with the range of reported values for the unlabeled and cysteine-free SpA, Bd, and other single (and double) domains ($2-70 nM) [5, 33, 36, 37] .
Previous studies employing radioimmunoassay have found that the affinities of SpA for guinea pig and rabbit IgG are similar [3, 31, 38] . However, the K D and EC 50 determinations from the SPR and FA experiments, respectively, indicate that the affinity of Bdcys conjugates for the anti-GABA A -a1 antibody exceeds that for the anti-GABA A -q1 antibody (Fig. 3A, Fig. 5A -D, and Table 1 ). This relationship is also consistent with the results obtained by ELISA (Fig. 2) . The higher affinity of Bd-cys for the anti-GABA A -a1 could reflect a tighter binding of SpA (and its domains) to rabbit IgG as compared with guinea pig IgG. That is, because SpA and its domains bind to the Fc fragment and not the Fab fragment of IgG, the binding of SpA and Bd to IgG is species and isotype dependent. Alternatively, the evident difference in relative affinity for anti-GABA A -a1 versus anti-GABA A -q1 determined by SPR and FA could reflect a differential sensitivity of the two analytical techniques to signals arising from complexes in which anti-GABA A -a1 and anti-GABA A -q1 participate.
The current study included tests of the activity of Bd-cys dimer, a moiety present in Bd-cys monomer preparations (Fig. 1) . The FA data indicate that FL-labeled Bd-cys dimer has substantial affinity for the investigated anti-GABA A -q1 and anti-GABA A -a1 antibodies, although the affinity of the dimer for a given antibody appears less than that exhibited by the Bd-cys monomer preparation (Fig. 5) . This somewhat lower antibody-binding affinity of FL-labeled dimer might be a consequence of masking, by the FL label, of residues that are within the IgG-binding region of the dimer [35] . In addition, the ELISA results of Fig. 2 indicate significantly lower net absorbance values for the FL-labeled Bd-cys dimer than for unlabeled Bd-cys dimer and the FL-labeled monomer, indicating relatively weak antibody binding for the FL-labeled Bd-cys dimer. The larger difference observed in the ELISA assay for the antibody-binding affinities of FL-labeled Bd-cys dimer versus FLlabeled monomer could be due to the use of different antibodies in the ELISA versus FA experiments. Because the streptavidincoated surface of the SPR flow cell captured only (monomeric) Bd-cys-S-PEG3400-biotin, Bd-cys dimer did not contribute to the detected SPR signals. In the FA experiments testing Bd-cys-S-FL, contaminating Bd-cys dimer (which lacked cys-S-conjugated FL) was not a reporting moiety but presumably bound antibodies in solution and rendered them unavailable for binding to the Bd-cys-S-FL. The evident variation among samples in the amount of dimer present (Fig. 1) could be due to differences in preparative conditions or to the difference in the maleimide compounds added (i.e., maleimide-FL vs. maleimide-PEG3400-biotin). A bulkier maleimide compound, for example, could exhibit a slower reaction with monomeric Bd-cys, allowing more time for reduced sulfhydryl groups to combine and form dimers.
The current findings extend the approach described by Mazzucchelli and coworkers [21] and demonstrate specifically the ability of Bd-cys, in combination with an SpA-binding antibody, to localize Bd-cys-bound compounds at transmembrane ion channels. In contrast to direct functionalization of the antibody through technologies that often yield conjugates of multiple and variable valency (e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide [EDC] coupling of the ligand to lysine residues), the approach studied here enables localization of the ligand at a single defined site on the Bd-cys scaffold and, thus (given the specificities of Bd's attachment to IgG and of IgG's attachment to the target protein), a uniformity of spatial positioning of the ligand relative to the target protein's structure. Of particular note is our finding that conjugation of Bd-cys with a long-chain PEG moiety (maleimide-PEG3400-biotin) preserves robust binding of the conjugate/ antibody complex to the target membrane protein. That is, both high-affinity interaction of the Bd-cys scaffold for anti-GABA A antibody and high-affinity interaction of the complex with the investigated GABA A receptors are maintained in the presence of the long, highly flexible PEG3400. Particularly in cases where the cysteine site of the Bd-cys may be relatively distant from the target protein's ligand-binding site, Bd-cys/antibody complexes that employ a long-chain linker for ligand tethering to Bd-cys may prove to be useful for achieving localized physiological control of GABA receptors as well as other transmembrane ion channels [18] [19] [20] .
